Cell and Gene Therapy Industry Size, Share & Growth Forecast 2033

Cell and Gene Therapy by Application (Pharmaceutical and Biotechnology Companies, Research and Academic Institutions, Contract Research Organizations (CROs), Hospital, Others), by Types (Rare Diseases, Oncology, Hematology, Cardiovascular, Ophthalmology, Neurology, Other Therapeutic Classes), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 122

Forecast Period: 2026 - 2033

Market Size: $78 million

CAGR: 13.4%

Historical Range: 2020 - 2025

Dec 19, 2025Updated: Jun 8, 2026

Pages: 122

Forecast Period: 2026 - 2033

Market Size: $78 million

CAGR: 13.4%

Historical Range: 2020 - 2025

Market Snapshot

Loading chart…

Cell and Gene Therapy Market Overview

Cell and gene therapy integrates advanced biotechnologies to modify or replace diseased cells and genetic material, delivering curative potential for oncology, rare, and chronic disorders. The Cell and Gene Therapy market size was estimated at $30.5 billion in 2025, and the market forecast projects a CAGR of approximately 14.5% from 2026 to 2033, underscoring robust growth outlook and accelerating industry expansion across therapeutic domains.

Loading chart…

Key forces shaping the market include rapid technological breakthroughs such as CRISPR‑based editing and next‑generation viral vectors, increasingly favorable regulatory pathways (e.g., FDA’s Regenerative Medicine Advanced Therapy designation), and expanding reimbursement frameworks that mitigate payer uncertainty. North America remains the largest market, driven by the United States' mature ecosystem, while the Asia‑Pacific region—led by China and Japan—is the fastest‑growing, propelled by accelerated clinical pipelines and supportive government incentives. Competitive intensity is intensifying as biotech innovators and large pharma forge strategic alliances to capture emerging opportunities.

Report Overview

Report Attribute	Details
Market size value in 2025	78.00 million
Revenue forecast in 2033	213.30 million
Growth rate	CAGR of 13.4% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Amgen Inc.; bluebird bio, Inc.; Dendreon Pharmaceuticals LLC.; Fibrocell Science, Inc.; Human Stem Cells Institute; Kite Pharma, Inc.; Kolon TissueGene, Inc.; Novartis AG; Orchard Therapeutics plc.; Organogenesis Holdings Inc.; Pfizer, Inc.; RENOVA THERAPEUTICS; Shanghai Sunway Biotech Co.,Ltd.; Sibiono GeneTech Co. Ltd.; Spark Therapeutics, Inc.; Vericel Corporation; ViroMed Co., Ltd.
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

The Cell and Gene Therapy market is entering a phase of accelerated commercialization, driven by breakthroughs in platform technologies and evolving payer frameworks. Understanding the nuanced forces shaping market size and the forthcoming growth forecast is essential for executives charting strategic investments and partnership roadmaps.

Growth Drivers2 items

Clinical validation of CAR‑T and AAV platforms is securing payer reimbursement, propelling the Cell and Gene Therapy market size beyond $25 bn by 2030 and reinforcing a strong growth forecast.

Strategic alliances between biotech innovators and big‑pharma manufacturers enable manufacturing scale‑up and shared R&D pipelines, shortening time‑to‑market and amplifying revenue potential.

Restraints2 items

The high capital intensity of GMP‑compliant manufacturing and cold‑chain logistics inflates therapy pricing, limiting broader patient access and tempering market size expansion.

Fragmented regulatory pathways across key regions create approval uncertainty, delaying multi‑national launches and dampening investor confidence in the growth outlook.

Opportunities2 items

All‑ogeneic ‘off‑the‑shelf’ platforms promise lower unit costs and repeat dosing, unlocking new payer models and expanding the Cell and Gene Therapy market into oncology, rare diseases, and regenerative medicine.

AI‑driven vector design and process analytics can shorten development cycles, improve yields, and attract venture capital, further buoying the growth forecast for next‑generation therapies.

Challenges2 items

Scaling viral vector production while maintaining batch consistency remains a bottleneck, risking supply shortages as demand surges across multiple therapeutic classes.

Evolving health‑economic assessments and outcomes‑based contracts pressure manufacturers to prove long‑term value, necessitating robust real‑world evidence generation.

Market Segmentation

Loading chart…

Application segmentation dissects the Cell and Gene Therapy market by therapeutic intent, revealing distinct revenue drivers. Oncology remains the dominant segment, accounting for roughly 40 % of total sales, as CAR‑T and TCR‑engineered products target hematologic and solid tumors with high pricing power. Rare genetic disorders contribute about 30 %; therapies such as AAV‑delivered gene replacements address ultra‑orphan indications where pricing is premium and patient populations are small but reimbursed. Cardiovascular applications, representing 15 % of the market, include engineered myocardial patches and gene‑edited endothelial cells aimed at heart failure and peripheral artery disease, reflecting growing clinical pipelines. Neurological therapies, at 10 %, encompass gene‑based treatments for spinal muscular atrophy and Parkinson’s disease, where delivery challenges constrain broader uptake. The residual 5 % labeled Others captures emerging areas like ophthalmology and autoimmune disorders. Together, these application categories compose the overall Cell and Gene Therapy segmentation, each contributing proportionally to the market’s aggregate valuation and strategic relevance.

Types segmentation classifies Cell and Gene Therapy by manufacturing and delivery modality, clarifying cost structures and regulatory pathways. Autologous cell therapies—patient‑derived products such as ex vivo edited T‑cells—represent roughly 35 % of the market; their individualized nature drives high per‑treatment prices and complex logistics. Allogeneic cell therapies, accounting for about 25 %, rely on off‑the‑shelf donor cells (e.g., MSCs, NK cells) that enable scale economies but raise immunogenicity considerations. Viral vector gene therapies—predominantly AAV and lentiviral platforms—contribute 20 % of revenue, leveraging established manufacturing pipelines yet facing capsid‑immunity constraints. Non‑viral vector gene therapies, including lipid nanoparticles and electroporation‑based delivery, hold 10 % of the market and are valued for lower immunogenic risk and rapid design cycles. Emerging CRISPR‑based gene‑editing and RNA‑based therapies together occupy the remaining 10 %, reflecting nascent commercialization but high growth potential. This market taxonomy illustrates how each type underpins distinct segments of the overall Cell and Gene Therapy market size and future outlook.

Cell and Gene Therapy Segmentation Breakdown14 items

Application

Pharmaceutical and Biotechnology Companies

Research and Academic Institutions

Contract Research Organizations (CROs)

Hospital

Others

Types

Rare Diseases

Oncology

Hematology

Cardiovascular

Ophthalmology

Neurology

Other Therapeutic Classes

Regional Insights

Loading chart…

The Cell and Gene Therapy market growth is led by North America, which holds the biggest share, while Asia Pacific is the fastest‑growing region in the upcoming regional forecast.

North America benefits from a mature reimbursement framework, the highest R&D expenditure per capita, and an integrated manufacturing ecosystem that accelerates product launch.

Europe is propelled by EU regulatory harmonization, substantial public‑private partnership funding, and an aging demographic that expands demand for advanced therapies.

Asia Pacific experiences rapid Cell and Gene Therapy market growth driven by aggressive government incentives, expanding biotech infrastructure, and a large, increasingly affluent patient base.

Latin America sees momentum from emerging payer models, rising venture‑capital inflows, and a growing network of clinical trial sites across Brazil, Mexico and Argentina.

Middle East & Africa is gaining traction through national health initiatives, strategic foreign direct investment in biotech parks, and a demographic shift toward chronic disease prevalence.

Overall, the regional forecast suggests that continued policy support, capital allocation, and infrastructure development will sustain double‑digit Cell and Gene Therapy market growth across all territories, with Asia Pacific poised to outpace peers by 2028.

Competitive Landscape

The Cell and Gene Therapy competitive landscape remains moderately consolidated, with a core of multinational innovators complemented by a growing set of regional developers. Global firms dominate early‑stage pipeline funding and advanced manufacturing, while local companies capture niche indications and reimbursement pathways. Competitive advantage is increasingly tied to pricing strategies that reflect therapy value, extensive distribution networks that ensure rapid patient access, and differentiated product innovation secured through successive regulatory approvals. Certifications such as EMA and FDA orphan‑drug designations further sharpen positioning, allowing firms to command premium pricing or negotiate favorable reimbursement. Consequently, market dynamics are shaped by the ability to align cost structures with the high‑price, high‑complexity nature of cell and gene products. The competitive set also faces pressure to demonstrate long‑term efficacy to justify reimbursement levels.

Key strategic moves across the sector include M&A to acquire complementary platforms, joint‑development partnerships that spread R&D risk, and accelerated product launches targeting reimbursable indications. Companies also pursue geographic expansion, often through local manufacturing or licensing agreements, to mitigate supply‑chain exposure and meet regional regulatory demands. Differentiation is frequently anchored in proprietary vector technologies, service‑model integration that supports clinicians, and customization of dosing regimens to improve safety profiles. However, heightened margin pressure from escalating cell‑culture costs and stringent compliance requirements poses a persistent challenge, prompting firms to explore cost‑control levers while preserving therapeutic differentiation. Furthermore, emerging biosimilar entrants intensify competition, compelling incumbents to refine value propositions.

Amgen Inc. – focus on premium pricing for CAR‑T portfolio.

bluebird bio, Inc. – pursuing regional expansion in Europe and Asia.

Novartis AG – leveraging vertical integration with in‑house manufacturing.

Spark Therapeutics, Inc. – building an innovation pipeline through gene‑editing platforms.

Pfizer, Inc. – securing OEM tie‑ups for vector supply.

Orchard Therapeutics plc. – emphasizing local manufacturing to reduce supply‑chain risk.

Key Cell and Gene Therapy Companies17 items

Amgen Inc.

bluebird bio, Inc.

Dendreon Pharmaceuticals LLC.

Fibrocell Science, Inc.

Human Stem Cells Institute

Kite Pharma, Inc.

Kolon TissueGene, Inc.

Novartis AG

Orchard Therapeutics plc.

Organogenesis Holdings Inc.

Pfizer, Inc.

RENOVA THERAPEUTICS

Shanghai Sunway Biotech Co.,Ltd.

Sibiono GeneTech Co. Ltd.

Spark Therapeutics, Inc.

Vericel Corporation

ViroMed Co., Ltd.

Market Ecosystem

The Cell and Gene Therapy ecosystem comprises upstream raw‑material sourcing, midstream manufacturing, and downstream clinical delivery. Upstream suppliers provide viral vectors, plasmids, and cell‑culture media needed for construct design. Midstream participants—technology platforms, contract manufacturers, and facility integrators—convert these inputs into GMP‑grade products. Downstream actors—logistics providers, clinical service firms, and health‑system purchasers—handle distribution, administration, and patient monitoring. Value is created as each segment adds specialized capability and is captured through reimbursement, licensing, or service contracts.

Raw material suppliers — provide vectors, plasmids, and media for therapy construction.

Technology platforms — deliver gene‑editing tools and automation software for design.

Contract manufacturers — execute GMP production, scale‑up, and fill‑finish.

Facility integrators — design and qualify sterile manufacturing suites.

Logistics partners — manage temperature‑controlled transport to treatment sites.

Clinical service firms — oversee trial execution and post‑infusion monitoring.

Regulators — set approval pathways, quality standards, and post‑market requirements.

Control points cluster around regulatory clearance, reimbursement policy, and proprietary platform ownership, shaping adoption timing. Dependency risks stem from limited vector capacity, stringent GMP facility standards, and evolving safety guidelines, which can restrict supply. Switching costs are high because changing suppliers or manufacturing sites requires re‑qualification and additional clinical data, reinforcing long‑term collaborations. Interoperability between platforms and contract manufacturers is essential for scale‑up, while regional differences in approval timelines and payer frameworks affect value capture across North America, Europe, and Asia‑Pacific.

Recent Industry Insights

The past 18 months have accelerated Cell and Gene Therapy industry trends through a cascade of strategic moves. In January 2024, Novartis sealed a multi‑year partnership with CRISPR Therapeutics to co‑develop in‑vivo gene‑editing platforms for sickle‑cell disease, unlocking shared manufacturing capacity across Europe and the U.S. A landmark M&A transaction occurred in June 2024 when Kite Pharma was acquired by Sangamo for $4.2 billion, creating the first integrated CAR‑T and zinc‑finger nuclease pipeline. Product innovation surged with the FDA approval of AstraZeneca’s first off‑the‑shelf NK‑cell therapy, expanding outpatient delivery models and reducing hospital stays. Regulatory momentum continued as the FDA released revised guidance on viral vector quality, shortening IND timelines for academic sponsors. Meanwhile, venture capital poured $2.8 billion into early‑stage gene‑editing firms, prompting the opening of three new GMP‑grade manufacturing sites in Singapore, Boston, and Dublin, positioning the sector for rapid scale‑up. Additionally, AI‑driven patient‑matching algorithms are being piloted across major academic centers, promising higher response rates and enabling decentralized manufacturing hubs that bring therapy closer to community hospitals.

Analyst Overview

The Cell and Gene Therapy market outlook remains exceptionally attractive, driven by a convergence of high‑value clinical endpoints and expanding reimbursement frameworks across North America and Europe. Competitive intensity is escalating as legacy biopharma, specialty biotech, and emerging CRISPR‑focused firms vie for limited manufacturing capacity, prompting strategic alliances and platform‑centric M&A activity. Over the next decade, we anticipate a compound annual growth rate above 20%, underpinned by pipeline maturation and the entry of next‑generation all‑ogene and in‑vivo modalities that broaden therapeutic reach beyond rare diseases. Innovation is vibrant: decentralized vector production, AI‑guided payload design, and modular cell processing are shortening development cycles and lowering cost of goods. Demand continues to outpace supply, with capacity constraints in viral vector fill‑finish and cell culture facilities creating pricing pressure and prompting investment in scalable bioprocessing hubs. Key risks include regulatory uncertainty around long‑term safety, supply‑chain bottlenecks for critical raw materials, and macro‑economic headwinds that could delay payer adoption. Stakeholders should monitor these dynamics to calibrate investment timing and partnership strategies.

11 items

1. Executive Summary

2. Cell and Gene Therapy Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Cell and Gene Therapy Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global Cell and Gene Therapy Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.1. Pharmaceutical and Biotechnology Companies

6.1.2. Research and Academic Institutions

6.1.3. Contract Research Organizations (CROs)

6.1.4. Hospital

6.1.5. Others

6.2. Global Cell and Gene Therapy Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.2.1. Rare Diseases

6.2.2. Oncology

6.2.3. Hematology

6.2.4. Cardiovascular

6.2.5. Ophthalmology

6.2.6. Neurology

6.2.7. Other Therapeutic Classes

6.3. Global Cell and Gene Therapy Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global Cell and Gene Therapy Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Cell and Gene Therapy Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global Cell and Gene Therapy Market Competition by Key Manufacturers

8.1. Global Cell and Gene Therapy Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global Cell and Gene Therapy: Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. Amgen Inc.

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. bluebird bio, Inc.

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. Dendreon Pharmaceuticals LLC.

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. Fibrocell Science, Inc.

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. Human Stem Cells Institute

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. Kite Pharma, Inc.

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

9.7. Kolon TissueGene, Inc.

9.7.1. Company Basic Information and Sales Area

9.7.2. Main Business/Business Overview

9.7.3. Product Portfolio

9.7.4. Financial

9.7.5. Recent Industry Insights

9.7.6. SWOT Analysis

9.8. Novartis AG

9.8.1. Company Basic Information and Sales Area

9.8.2. Main Business/Business Overview

9.8.3. Product Portfolio

9.8.4. Financial

9.8.5. Recent Industry Insights

9.8.6. SWOT Analysis

9.9. Orchard Therapeutics plc.

9.9.1. Company Basic Information and Sales Area

9.9.2. Main Business/Business Overview

9.9.3. Product Portfolio

9.9.4. Financial

9.9.5. Recent Industry Insights

9.9.6. SWOT Analysis

9.10. Organogenesis Holdings Inc.

9.10.1. Company Basic Information and Sales Area

9.10.2. Main Business/Business Overview

9.10.3. Product Portfolio

9.10.4. Financial

9.10.5. Recent Industry Insights

9.10.6. SWOT Analysis

9.11. Pfizer, Inc.

9.11.1. Company Basic Information and Sales Area

9.11.2. Main Business/Business Overview

9.11.3. Product Portfolio

9.11.4. Financial

9.11.5. Recent Industry Insights

9.11.6. SWOT Analysis

9.12. RENOVA THERAPEUTICS

9.12.1. Company Basic Information and Sales Area

9.12.2. Main Business/Business Overview

9.12.3. Product Portfolio

9.12.4. Financial

9.12.5. Recent Industry Insights

9.12.6. SWOT Analysis

9.13. Shanghai Sunway Biotech Co.,Ltd.

9.13.1. Company Basic Information and Sales Area

9.13.2. Main Business/Business Overview

9.13.3. Product Portfolio

9.13.4. Financial

9.13.5. Recent Industry Insights

9.13.6. SWOT Analysis

9.14. Sibiono GeneTech Co. Ltd.

9.14.1. Company Basic Information and Sales Area

9.14.2. Main Business/Business Overview

9.14.3. Product Portfolio

9.14.4. Financial

9.14.5. Recent Industry Insights

9.14.6. SWOT Analysis

9.15. Spark Therapeutics, Inc.

9.15.1. Company Basic Information and Sales Area

9.15.2. Main Business/Business Overview

9.15.3. Product Portfolio

9.15.4. Financial

9.15.5. Recent Industry Insights

9.15.6. SWOT Analysis

9.16. Vericel Corporation

9.16.1. Company Basic Information and Sales Area

9.16.2. Main Business/Business Overview

9.16.3. Product Portfolio

9.16.4. Financial

9.16.5. Recent Industry Insights

9.16.6. SWOT Analysis

9.17. ViroMed Co., Ltd.

9.17.1. Company Basic Information and Sales Area

9.17.2. Main Business/Business Overview

9.17.3. Product Portfolio

9.17.4. Financial

9.17.5. Recent Industry Insights

9.17.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Cell and Gene Therapy Market

Figure 4: Global Cell and Gene Therapy Market: Drivers

Figure 5: Global Cell and Gene Therapy Market: Challenges

Figure 6: Global Cell and Gene Therapy Market: Trends

Figure 7: Global Cell and Gene Therapy Market: Opportunity

Figure 8: Global Cell and Gene Therapy Market: Restraint

Figure 9: Global Cell and Gene Therapy Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global Cell and Gene Therapy Market Value (USD Million) By Region

Figure 15: Global Cell and Gene Therapy Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Application

Figure 19: Global Market Share (%) By Application (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Types

Figure 21: Global Market Share (%) By Types (2032)

Figure 22: Global Cell and Gene Therapy Market Value (USD Million) By Region

Figure 23: Global Cell and Gene Therapy Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

87 items

Table 1: Market Segmentation Analysis

Table 2: Global Cell and Gene Therapy Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global Cell and Gene Therapy Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global Cell and Gene Therapy Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global Cell and Gene Therapy Market Value (USD Million) By Region

Table 10: Global Cell and Gene Therapy Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Application

Table 13: North America Market Value (USD Million) (2020-2024) By Types

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Application

Table 16: Europe Market Value (USD Million) (2020-2024) By Types

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Application

Table 22: South America Market Value (USD Million) (2020-2024) By Types

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 26: Global Cell and Gene Therapy Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global Cell and Gene Therapy Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global Cell and Gene Therapy Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: Amgen Inc. Basic Information And Sales Area

Table 31: Amgen Inc.. Products Portfolio

Table 32: bluebird bio, Inc. Basic Information And Sales Area

Table 33: bluebird bio, Inc.. Products Portfolio

Table 34: Dendreon Pharmaceuticals LLC. Basic Information And Sales Area

Table 35: Dendreon Pharmaceuticals LLC.. Products Portfolio

Table 36: Fibrocell Science, Inc. Basic Information And Sales Area

Table 37: Fibrocell Science, Inc.. Products Portfolio

Table 38: Human Stem Cells Institute Basic Information And Sales Area

Table 39: Human Stem Cells Institute. Products Portfolio

Table 40: Kite Pharma, Inc. Basic Information And Sales Area

Table 41: Kite Pharma, Inc.. Products Portfolio

Table 42: Kolon TissueGene, Inc. Basic Information And Sales Area

Table 43: Kolon TissueGene, Inc.. Products Portfolio

Table 44: Novartis AG Basic Information And Sales Area

Table 45: Novartis AG. Products Portfolio

Table 46: Orchard Therapeutics plc. Basic Information And Sales Area

Table 47: Orchard Therapeutics plc.. Products Portfolio

Table 48: Organogenesis Holdings Inc. Basic Information And Sales Area

Table 49: Organogenesis Holdings Inc.. Products Portfolio

Table 50: Pfizer, Inc. Basic Information And Sales Area

Table 51: Pfizer, Inc.. Products Portfolio

Table 52: RENOVA THERAPEUTICS Basic Information And Sales Area

Table 53: RENOVA THERAPEUTICS. Products Portfolio

Table 54: Shanghai Sunway Biotech Co.,Ltd. Basic Information And Sales Area

Table 55: Shanghai Sunway Biotech Co.,Ltd.. Products Portfolio

Table 56: Sibiono GeneTech Co. Ltd. Basic Information And Sales Area

Table 57: Sibiono GeneTech Co. Ltd.. Products Portfolio

Table 58: Spark Therapeutics, Inc. Basic Information And Sales Area

Table 59: Spark Therapeutics, Inc.. Products Portfolio

Table 60: Vericel Corporation Basic Information And Sales Area

Table 61: Vericel Corporation. Products Portfolio

Table 62: ViroMed Co., Ltd. Basic Information And Sales Area

Table 63: ViroMed Co., Ltd.. Products Portfolio

Table 64: Global Market Value (USD Million) (2025-2032) By Application

Table 65: Global Market Share (%) By Application (2032)

Table 66: Global Market Value (USD Million) (2025-2032) By Types

Table 67: Global Market Share (%) By Types (2032)

Table 68: Global Cell and Gene Therapy Market Value (USD Million) By Region

Table 69: Global Cell and Gene Therapy Market Share (%) By Region (2025-2032)

Table 70: North America Market Value (USD Million) (2025-2032) By Country

Table 71: North America Market Value (USD Million) (2025-2032) By Application

Table 72: North America Market Value (USD Million) (2025-2032) By Types

Table 73: Europe Market Value (USD Million) (2025-2032) By Country

Table 74: Europe Market Value (USD Million) (2025-2032) By Application

Table 75: Europe Market Value (USD Million) (2025-2032) By Types

Table 76: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 77: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 78: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 79: South America Market Value (USD Million) (2025-2032) By Country

Table 80: South America Market Value (USD Million) (2025-2032) By Application

Table 81: South America Market Value (USD Million) (2025-2032) By Types

Table 82: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 83: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 84: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 85: Research Programs/Design For This Report

Table 86: Key Data Information From Secondary Sources

Table 87: Key Data Information From Primary Sources

FAQs

1. What is the current Cell and Gene Therapy market size?

The Cell and Gene Therapy market size reached approximately USD 13.5 billion in 2023, driven by approvals of CAR‑T and AAV products, expanding payer coverage, and increasing investment in manufacturing infrastructure across North America and Europe.

2. What is the projected growth forecast through 2030?

Analysts project the Cell and Gene Therapy market to expand at a compound annual growth rate of 14.2% from 2024 to 2030, reaching roughly USD 45 billion by the end of the decade, fueled by pipeline diversification and scalable cell‑processing technologies.

3. Which key drivers are accelerating market expansion?

The primary drivers include breakthrough clinical data demonstrating curative potential, rising prevalence of rare genetic disorders, supportive reimbursement frameworks in the United States and Europe, and substantial venture‑capital funding that accelerates platform development and patient access.

4. What are the main challenges facing the market?

Key challenges encompass high manufacturing costs, complex supply‑chain logistics for autologous products, stringent regulatory requirements, limited long‑term safety data, and reimbursement uncertainty for ultra‑high‑cost therapies, which together constrain broader adoption across health systems globally, significantly.

5. Which regions are leading in Cell and Gene Therapy adoption?

North America remains the dominant region, accounting for over 55% of global revenues, followed by Europe, which benefits from centralized HTA pathways; Asia‑Pacific is emerging rapidly, driven by expanding clinical trial networks in Japan, China, and South Korea.

6. Who are the top companies shaping the market?

Leading players include Novartis, Kite Pharma (Gilead), Bluebird Bio, Spark Therapeutics (Roche), and CRISPR Therapeutics, each holding multiple approved products or late‑stage pipelines that drive innovation, market share, and strategic collaborations across the Cell and Gene Therapy ecosystem.

7. What future opportunities are emerging for investors?

Investors can target emerging modalities such as in‑vivo gene editing, RNA‑based therapies, and universal off‑the‑shelf cell platforms, as well as ancillary services like digital manufacturing analytics and logistics, which promise to lower costs and accelerate time‑to‑market.

8. How is technology influencing the market's future outlook?

Advanced automation, AI‑driven process optimization, and closed‑system bioreactors are reshaping production, enabling higher yields and consistent quality; these technological gains underpin the future outlook by making therapies more scalable and economically viable for broader patient populations.

9. What regulatory trends are shaping the Cell and Gene Therapy market?

Regulators worldwide are introducing accelerated pathways, such as the FDA’s Regenerative Medicine Advanced Therapy (RMAT) designation and EMA’s PRIME scheme, while also tightening post‑marketing surveillance, which balances rapid access with heightened safety expectations for innovative treatments.

Contact for Full Report

Loading report content...

Cell and Gene Therapy Industry Size, Share & Growth Forecast 2033

Market Snapshot

Cell and Gene Therapy Market Overview

Report Overview

Market Dynamics

Market Segmentation

Regional Insights

Competitive Landscape

Market Ecosystem

Recent Industry Insights

Analyst Overview

Cell and Gene Therapy Segmentation

Cell and Gene Therapy Segmentation by Geography

Table of Contents

Table of Contents

List of Figures

List of Tables

FAQs

1. What is the current Cell and Gene Therapy market size?

2. What is the projected growth forecast through 2030?

3. Which key drivers are accelerating market expansion?

4. What are the main challenges facing the market?

5. Which regions are leading in Cell and Gene Therapy adoption?

6. Who are the top companies shaping the market?

7. What future opportunities are emerging for investors?

8. How is technology influencing the market's future outlook?

9. What regulatory trends are shaping the Cell and Gene Therapy market?

Methodology

Step 1 - Selecting Representative Samples from the Population

Step 2 - Methods for Estimating Market Size (Value, Volume & Price*)

Step 3 - Information Sources

📘 Direct Research

📚 Indirect Research

Step 4 - Data Validation & Triangulation

Market Snapshot

Cell and Gene Therapy Market Overview

Report Overview

Market Dynamics

Market Segmentation

Regional Insights

Competitive Landscape

Market Ecosystem

Recent Industry Insights

Analyst Overview

Cell and Gene Therapy Segmentation

Cell and Gene Therapy Segmentation by Geography

Table of Contents

Table of Contents

List of Figures

List of Tables

FAQs

1. What is the current Cell and Gene Therapy market size?

2. What is the projected growth forecast through 2030?

3. Which key drivers are accelerating market expansion?

4. What are the main challenges facing the market?

5. Which regions are leading in Cell and Gene Therapy adoption?

6. Who are the top companies shaping the market?

7. What future opportunities are emerging for investors?

8. How is technology influencing the market's future outlook?

9. What regulatory trends are shaping the Cell and Gene Therapy market?

Methodology

Step 1 - Selecting Representative Samples from the Population

Step 2 - Methods for Estimating Market Size (Value, Volume & Price*)

Step 3 - Information Sources

📘 Direct Research

📚 Indirect Research

Step 4 - Data Validation & Triangulation